Machina Capital S.A.S. Acquires Shares of 4,169 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Machina Capital S.A.S. bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,169 shares of the company’s stock, valued at approximately $549,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Forsta AP Fonden acquired a new position in Neurocrine Biosciences in the 3rd quarter valued at about $2,048,000. New York State Teachers Retirement System increased its stake in shares of Neurocrine Biosciences by 0.8% during the third quarter. New York State Teachers Retirement System now owns 96,989 shares of the company’s stock worth $10,911,000 after purchasing an additional 740 shares during the period. BluePath Capital Management LLC acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $35,000. Mackenzie Financial Corp boosted its stake in Neurocrine Biosciences by 3.5% in the 3rd quarter. Mackenzie Financial Corp now owns 95,631 shares of the company’s stock valued at $10,568,000 after purchasing an additional 3,277 shares during the period. Finally, IFM Investors Pty Ltd grew its holdings in Neurocrine Biosciences by 2.9% in the 3rd quarter. IFM Investors Pty Ltd now owns 18,233 shares of the company’s stock valued at $2,051,000 after buying an additional 511 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Guggenheim boosted their target price on shares of Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a research report on Thursday. Canaccord Genuity Group increased their target price on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a “buy” rating in a research report on Thursday. Barclays lifted their price target on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a research report on Thursday. Mizuho increased their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research report on Thursday, February 8th. Finally, Citigroup upped their target price on Neurocrine Biosciences from $140.00 to $150.00 and gave the company a “neutral” rating in a research report on Friday. Six analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $147.88.

Neurocrine Biosciences Price Performance

NBIX stock traded up $1.00 during midday trading on Monday, reaching $141.71. 483,775 shares of the stock were exchanged, compared to its average volume of 849,714. The stock has a market capitalization of $14.26 billion, a PE ratio of 39.04 and a beta of 0.28. Neurocrine Biosciences, Inc. has a 52 week low of $89.04 and a 52 week high of $148.37. The company has a fifty day moving average price of $137.49 and a 200 day moving average price of $129.22.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The company had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. During the same period in the previous year, the business posted $0.88 earnings per share. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 4.78 earnings per share for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider David W. Boyer sold 456 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the completion of the sale, the insider now directly owns 4,894 shares in the company, valued at $694,752.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 3,040 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $142.18, for a total transaction of $432,227.20. Following the completion of the transaction, the chief executive officer now owns 504,919 shares in the company, valued at approximately $71,789,383.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David W. Boyer sold 456 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total transaction of $64,733.76. Following the completion of the sale, the insider now directly owns 4,894 shares in the company, valued at $694,752.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 181,547 shares of company stock worth $25,039,887. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.